cas 1571-08-0|| where to buy Methyl 4-formylbenzoate

Produktname:Methyl 4-formylbenzoate

IUPAC Name:methyl 4-formylbenzoate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM157703-1000g	in stock	Ȧǧ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1571-08-0 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1571-08-0; Molekulare Formel:C9H8O3; Schmelzpunkt:-; SMILES-Code:C1=C(C(OC)=O)C=CC(=C1)C=O; Dichte:

: Katalognummer:CM157703; Molekulargewicht:164.16; Siedepunkt:265°C at 760 mmHg; Mdl-Nr.:MFCD00006950; Lagerung:Keep in Inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Risvodetinib; Inhibikase Therapeutics’s Risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Multiple System Atrophy (MSA). MSA is a rapidly progressive rare condition of the nervous system that causes gradual damage to nerve cells in the brain, and shares many symptoms with Parkinson's disease. This neurological disorder has an estimate an average of 0.6 to 0.7 new cases per 100,000 people yearly.
The non-receptor tyrosine kinase Abelson, c-Abl is shown to be implicated in the initiation and progression of α-synuclein (α-syn) pathogenesis and neurodegeneration. Risvodetinib is a brain-penetrant selective inhibitor of c-Abl1 and Abl2 undergoing Phase 2 clinical studies.